Article and Video CATEGORIES
Choices Among Immunotherapeutics May Be the Future of Lung Cancer Care
Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action in the same clinical settings?
[powerpress]
Please feel free to offer comments and raise questions in our Discussion Forums.
Tags
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Recent Comments
Hi Hopish hope, Welcome to…
By JanineT GRACE … on
colon cancer and HIV
By Hopish hope on